We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Sangamo Therapeutics Inc | NASDAQ:SGMO | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.0426 | 7.13% | 0.64 | 0.6101 | 0.64 | 0.6492 | 0.604 | 0.6097 | 1,070,259 | 01:00:00 |
From May 2019 to May 2024
RICHMOND, Calif., Aug. 30, 2018 /PRNewswire/ -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO) announced today that management will host a conference call on September 5th at 9:00 a.m. ET to discuss clinical data from the CHAMPIONS Study, the Company's Phase 1/2 trial evaluating SB-913 in vivo genome editing therapeutic candidate for MPS II. The call will follow the presentation of the data earlier that day at the 2018 Symposium of the Society for the Study of Inborn Errors of Metabolism in Athens, Greece.
Sangamo also announced today that management will participate in the following healthcare investor conferences in September.
Sangamo's presentation is scheduled for 9:10 a.m. ET on Thursday, September 6th.
The Wells Fargo presentation will be webcast live and may be accessed via a link on the Sangamo Therapeutics website in the Investors and Media section under Events and Presentations. The presentation will be archived on the Sangamo website for two weeks after the event.
Sangamo's presentation is scheduled for 3:25 p.m. BST on Wednesday, September 12th.
Webcasting services are not provided at the Bank of America Merrill Lynch conference.
SB-913 Conference Call
Sangamo will host a conference call on September 5, 2018, at 9:00 a.m. ET, which will be open to the public. The call will also be webcast live and can be accessed via a link on the Sangamo Therapeutics website in the Investors and Media section under Events and Presentations.
The conference call dial-in numbers are (877) 377-7553 for domestic callers and (678) 894-3968 for international callers. The conference ID number for the call is 8798741. For those unable to listen in at the designated time, a conference call replay will be available for one week following the conference call. The conference call replay numbers for domestic and international callers are (855) 859-2056 and (404) 537-3406, respectively. The conference ID number for the replay is 8798741.
About Sangamo Therapeutics
Sangamo Therapeutics, Inc. is focused on translating ground-breaking science into genomic therapies that transform patients' lives using the Company's platform technologies in genome editing, gene therapy, gene regulation and cell therapy. For more information about Sangamo, visit www.sangamo.com.
View original content with multimedia:http://www.prnewswire.com/news-releases/sangamo-therapeutics-announces-conference-call-to-review-sb-913-champions-study-data-and-participation-at-upcoming-investor-conferences-300704736.html
SOURCE Sangamo Therapeutics, Inc.
Copyright 2018 PR Newswire
1 Year Sangamo Therapeutics Chart |
1 Month Sangamo Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
